Comparison of Mineral Trioxide Aggregate (MTA) and 20% Formocresol (FC) in Pulpotomized Human Primary Molars
Status:
Unknown status
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This prospective clinical randomized controlled trial is established to compare the clinical,
radiographic, and histological treatment outcomes between MTA and FC in pulpotomized human
primary molars at 6, 12, 18, 24 month post-treatment and to test the hypothesis that Gray
Mineral Trioxide Aggregate (GMTA) is a viable alternative to Diluted (20%) Formocresol (DFC)
in pulpotomies treatment of human primary molars.